Literature DB >> 9310463

Intensifying induction therapy in acute myeloid leukemia: has a new standard of care emerged?

J M Rowe, M S Tallman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9310463

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  12 in total

1.  Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups.

Authors:  Marlise R Luskin; Ju-Whei Lee; Hugo F Fernandez; Omar Abdel-Wahab; John M Bennett; Rhett P Ketterling; Hillard M Lazarus; Ross L Levine; Mark R Litzow; Elisabeth M Paietta; Jay P Patel; Janis Racevskis; Jacob M Rowe; Martin S Tallman; Zhuoxin Sun; Selina M Luger
Journal:  Blood       Date:  2016-01-11       Impact factor: 22.113

2.  Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.

Authors:  Ruben A Mesa; David Loegering; Heather L Powell; Karen Flatten; Sonnet J H Arlander; Nga T Dai; Michael P Heldebrant; Benjamin T Vroman; B Douglas Smith; Judith E Karp; Cynthia J Ten Eyck; Charles Erlichman; Scott H Kaufmann; Larry M Karnitz
Journal:  Blood       Date:  2005-03-22       Impact factor: 22.113

3.  Anthracycline dose intensification in acute myeloid leukemia.

Authors:  Hugo F Fernandez; Zhuoxin Sun; Xiaopan Yao; Mark R Litzow; Selina M Luger; Elisabeth M Paietta; Janis Racevskis; Gordon W Dewald; Rhett P Ketterling; John M Bennett; Jacob M Rowe; Hillard M Lazarus; Martin S Tallman
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

4.  High transcript level of FLT3 associated with high risk of relapse in pediatric acute myeloid leukemia.

Authors:  Hyoung Jin Kang; Ji Won Lee; Sang Hyeok Kho; Min Jeong Kim; Young Jin Seo; Hyery Kim; Hee Young Shin; Hyo Seop Ahn
Journal:  J Korean Med Sci       Date:  2010-05-24       Impact factor: 2.153

5.  Intensified daunorubicin in induction therapy and autologous peripheral blood stem cell transplantation in postremission therapy (Double-7 protocol) for adult acute myeloid leukemia.

Authors:  Noriko Usui; Nobuaki Dobashi; Osamu Asai; Shingo Yano; Yuichi Yahagi; Takeshi Saito; Yuko Yamaguchi; Kinuyo Kasama; Yutaka Okawa; Naohiro Sekiguchi; Yutaka Takei; Katsuki Sugiyama; Yoji Ogasawara; Hiroko Ohtsubo; Ken Kaito; Masayuki Kobayashi
Journal:  Int J Hematol       Date:  2002-12       Impact factor: 2.490

Review 6.  The evolving landscape in the therapy of acute myeloid leukemia.

Authors:  Grace L Peloquin; Yi-Bin Chen; Amir T Fathi
Journal:  Protein Cell       Date:  2013-08-27       Impact factor: 14.870

7.  Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis.

Authors:  Adi Diab; Lynette Zickl; Omar Abdel-Wahab; Suresh Jhanwar; Manjit A Gulam; Katherine S Panageas; Jay P Patel; Joseph Jurcic; Peter Maslak; Elisabeth Paietta; James K Mangan; Martin Carroll; Hugo F Fernandez; Julie Teruya-Feldstein; Selina M Luger; Dan Douer; Mark R Litzow; Hillard M Lazarus; Jacob M Rowe; Ross L Levine; Martin S Tallman
Journal:  Leuk Res       Date:  2012-10-24       Impact factor: 3.156

8.  Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML.

Authors:  Hagop M Kantarjian; Mikkael A Sekeres; Vincent Ribrag; Philippe Rousselot; Guillermo Garcia-Manero; Elias J Jabbour; Kate Owen; Paul K Stockman; Stuart D Oliver
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-06-10

9.  Long-term survivors with adult acute leukemia in complete remission: complications and return to work.

Authors:  Yuhko Suzuki-Tsunoda; Setsuko Kawamura; Kenichi Tsushima; Yoshiko Tamai; Hideki Takami; Akihiro Munakata; Masashi Tsunoda
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

10.  Meta-analysis of randomised clinical trials comparing idarubicin + cytarabine with daunorubicin + cytarabine as the induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia.

Authors:  Jing Wang; Yong-Gong Yang; Min Zhou; Jing-Yan Xu; Qi-Guo Zhang; Rong-Fu Zhou; Bing Chen; Jian Ouyang
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.